Improved MRD Response Rates with Ibrutinib and Obinutuzumab in Patients with CLL

Conference Correspondent —December 17, 2018


ASH 2018

Researchers have been evaluating whether achievement of minimal residual disease (MRD) can potentially serve as a marker for treatment interruption or stoppage in hematologic malignancies, including chronic lymphocytic leukemia (CLL). To date, few studies have evaluated the rate of MRD negativity among targeted agents in CLL. In the IcICLLe study, 20 treatment-naïve patients and 20 relapsed/refractory patients with CLL received ibrutinib until complete remission with <0.01% MRD in the peripheral blood and bone marrow or disease progression. Subsequently, the IcICLLe Extension Study continued IcICLLe to examine the efficacy and safety of ibrutinib plus obinutuzumab in 40 patients, 10 of whom had received prior ibrutinib on the IcICLLe trial. Initial results showed promise, and at the ASH 2018 Annual Meeting, researchers reported on the 18-month follow-up data.

Patients participating in the extension study received continuous ibrutinib with 6 cycles of obinutuzumab given over 6 months. MRD assessment was performed according to European Research Initiative on CLL guidelines with a maximum detection limit of 0.001%/10–5. In the 34 patients reaching Month 9 Disease Response Assessment, 5 of 10 (50%) of patients receiving prior ibrutinib treatment achieved MRD response at 3 months after completion of obinutuzumab treatment, compared with 2 of 30 (7%) ibrutinib-naïve patients at the same time point.

The addition of obinutuzumab was also associated with a greater depth of MRD depletion than observed in patients treated with ibrutinib monotherapy, particularly in patients who had received ibrutinib for at least 1 year before initiation of the extension study. Furthermore, peripheral blood MRD levels continued to improve in both groups of patients 6 months after obinutuzumab was discontinued.

Study results suggest that the addition of obinutuzumab to ibrutinib may result in a substantial improvement in the depletion of CLL cells, particularly when obinutuzumab was introduced after more than 1 year of ibrutinib treatment. The addition of obinutuzumab may be effective at improving MRD response rates, especially in patients whose tumor burden was already low after prior ibrutinib therapy.

Rawstron A, et al. ASH 2018. Abstract 181.

Related Articles
MURANO Study Explores Potential for Venetoclax-Rituximab Combination Therapy in Relapsed/Refractory CLL
Conference Correspondent
Researchers report promising findings for patients treated with a venetoclax-rituximab combination regimen in relapsed/refractory chronic lymphocytic leukemia (CLL).
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV
Conference Correspondent
The combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab achieved a high rate of undetectable minimal residual disease in previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL).
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL
Conference Correspondent
The ALLIANCE study showed that ibrutinib produces superior progression-free survival to standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL).
Last modified: December 17, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
  • Please enter your mailing address.

    Address Line 2
    Zip Code